Raymond James reiterates USD 19.00 target for Vir Biotechnology stock

Published on 10/01/2026 at 12:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 238.95 million in the second quarter, up 19,582.50 percent year over year. Vir Biotechnology stock has USD 1.9 billion market cap.

VIR, US92764N1028, Illustration mit AI erstellt.

Vir Biotechnology (US92764N1028) carries a USD 19.00 price target from Raymond James, which reiterated a Strong Buy rating on September 28, 2026, according to Investing.com. The call followed clinical results from Mirum Pharmaceuticals, while Raymond James said the data did not change its view of Vir's hepatitis delta programs.

Analyst target centers on hepatitis delta

The Raymond James target is USD 9.00 above the latest primary-market quote of USD 10.65 cited in the report, but the target and the reference quote are in different currencies from the required euro reference framework. The analyst expects Vir's tobevibart and elebsiran combination to compete with the approved Hepcludex treatment, according to Investing.com.

The immediate development calendar is also material. The same report says Vir's ECLIPSE 1 program is expected to deliver topline data in the fourth quarter of 2026, while ECLIPSE 2 and ECLIPSE 3 are expected in the first quarter of 2027.

Revenue and earnings turned positive

Vir reported USD 238.95 million of revenue in the second quarter of 2026, compared with USD 1.22 million in the same quarter of 2025, according to MarketBeat. The reported increase was 19,482.79 percent on those figures, while diluted earnings per share reached USD 0.47 versus a consensus estimate of USD 0.33.

Net income was USD 80.1 million in the second quarter of 2026, reversing a USD 121.0 million loss in the year-earlier period, according to Investing.com. That change gives the analyst target a financial backdrop, although the company's clinical programs remain the central valuation driver.

Market value and next reporting date

Vir Biotechnology had a market capitalization of USD 1.9 billion and a 52-week range of USD 4.82 to USD 11.94 as of September 30, 2026. A master-data listing identifies the company as a NASDAQ issuer under ticker VIR and gives November 4, 2026, as the next reporting date, according to wallstreetONLINE.